GM mosquitoes to check dengue menace?

Image
Press Trust of India New Delhi
Last Updated : Jul 27 2014 | 11:25 AM IST
A British company has approached Indian authorities seeking permission for technology trials of a certain genetically-modified mosquito claiming it will fight dengue menace.
The modified male mosquito named '513A' will have a gene that ensures its offspring dies before reaching adulthood (in 2-5 days) and thus control breeding of dengue spreading mosquitoes.
This genetically-modified mosquito has been tested in Brazil, where dengue emerged as a big worry during the recently concluded World Cup Football tournament, and the Cayman Islands.
UK-based Oxitec, an Oxford University spin-out which develops technologies for controlling insects, has approached the Indian government for necessary approvals to begin trials for GM mosquitoes here.
A company spokesperson told PTI from Oxford that the technology can be made available to public health authorities in India to help suppress the mosquitoes that spread dengue.
"Oxitec is working with GBIT, a privately held Indian company that specialises in developing and commercialising novel technologies in health and agriculture, with a view to introducing this technology for dengue vector control in India," the spokesperson said.
Thousands of dengue cases are reported every year in India.
"In due course, we would like to use the same approach for the main vectors of malaria but this work is at a very early stage," he said.
In the laboratory, the activity of this gene can be controlled by giving mosquitoes the antidote 'tetracycline'.
With regard to regulatory clearances, GBIT has already received nod for contained laboratory-based studies. Besides, permission for larger technology trials has been sought from the Review Committee for Genetic Manipulation (RCGM).
Field based studies would only begin following appraisal and approval by the relevant national bio safety committees, RCGM and Genetic Engineering Approval Committee (GEAC).
RCGM and GEAC come under the Ministry of Environment and Forests.
"We expect a large-scale trial to be the next step; however, the timing is entirely within the hands of the RCGM," the official noted.
As per Oxitec, dengue mosquito can also carry other diseases such as Chikungunya or Yellow Fever.
These GM male mosquitoes can mate only with females of the same species (dengue spreading), so that it is exclusively targeted to the dengue mosquito with no effect on other insect species.
"Every wild female which mates one of our modified males will have offspring who carry the gene and without the antidote, they won't survive.
"In this way, by repeatedly releasing Oxitec males, we can drastically reduce or even locally eliminate the dengue mosquito population," he said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 27 2014 | 11:25 AM IST

Next Story